# colorectal cancer - gemini-3.6-flash

- Benchmark system: raw
- Repeat: 4
- Task type: PROGNOSIS
- Tissue / sample source: colorectal tumor tissue
- Comparison or endpoint: overall survival (OS)
- Answer input cohort: Discovery/Core only
- Selected items: 100
- Input fields: gene name, effect size (log2FC/HR), P value, FDR
- E2seq Agent RAG: disabled
- Conversation memory: disabled
- Thinking mode: disabled
- Held-out validation data in prompt/RAG: no
- Model API: Google Gemini / gemini-3.6-flash
- Message SHA-256: dfb8fe82357dbea353d34030380d74028b528c91505f5793c7261ee9e4376675
- Response HTTP status: 200
- Prompt tokens: 5297
- Completion tokens: 11746
- Reasoning tokens: 
- Total tokens: 17043
- API requests reported: 
- Elapsed seconds: 20.632
- Final benchmark system: raw; file rank 3/5; original repeat 4; model vendor: Google Gemini

---
### 1. Overall Biological Interpretation

The provided transcriptomic dataset evaluates overall survival (OS) in colorectal cancer (CRC) tumor tissues. The risk-associated (hazard ratio [HR] $> 1$) and protective-associated ($\text{HR} < 1$) genes reveal two main transcriptomic axes governing colorectal cancer prognosis:

```
                      PROGNOSTIC AXIS IN COLORECTAL CANCER
                      
        Protective Signature (HR < 1)         Risk Signature (HR > 1)
     ┌───────────────────────────────┐     ┌───────────────────────────────┐
     │ • Lineage Differentiation     │     │ • Stromal / EMT Activation    │
     │   (CDX2, CDX1, MYB, MYO5B)    │     │   (INHBB, ZEB1-AS1, ITGBL1)   │
     │ • OXPHOS / TCA Bioenergetics  │ vs. │ • Cytoskeletal Remodeling     │
     │   (NDUFA9, ATP5B, CS, OGDHL)  │     │   (TPM4, ABL2, DCBLD2)        │
     │ • Antigen Presentation        │     │ • Immunosuppressive Adenosine │
     │   (TAPBPL, LGALS9)            │     │   (NT5E / CD73)               │
     └───────────────────────────────┘     └───────────────────────────────┘
```

1. **Epithelial Lineage Differentiation vs. Mesenchymal/Stromal Transition:** 
   Protective genes ($\text{HR} < 1$) are heavily enriched for homeobox transcription factors and structural markers that define committed intestinal epithelial identity (e.g., `CDX2`, `CDX1`, `MYB`, `MYO5B`, `LGALS4`). High expression of these genes reflects well-differentiated, organ-specific epithelial programs. Conversely, risk-associated genes ($\text{HR} > 1$) reflect activated TGF-$\beta$ signaling, non-coding RNA regulators of epithelial-to-mesenchymal transition (EMT), and extracellular matrix (ECM) structural components (e.g., `INHBB`, `ZEB1-AS1`, `MIR31HG`, `ITGBL1`, `TPM4`, `ADAMTS18`). This dichotomy aligns with the distinction between canonical/epithelial subtypes (such as CMS2/CMS3) and reactive/mesenchymal subtypes (such as CMS4, characterized by high stromal involvement and poor survival).

2. **Mitochondrial OXPHOS Bioenergetics vs. Glycolytic/Hypoxic Adaptation:** 
   Favorable prognosis is strongly associated with mitochondrial bioenergetic machinery, including electron transport chain subunits (`NDUFA9`, `ATP5B`, `ATP5G1`), assembly factors (`COA3`), and TCA cycle enzymes (`CS`, `OGDHL`). Conversely, unfavorable prognosis is marked by upregulated transport mechanisms associated with aggressive, hypoxic, or stromal metabolic rewiring, such as the high-affinity glucose transporter `SLC2A3` (GLUT3).

3. **Immune Surveillance vs. Microenvironmental Adenosinergic Suppression:** 
   Favorable survival aligns with intact antigen presentation pathway components (`TAPBPL`) and immune regulators (`LGALS9`, `CCL15`). In contrast, poor survival is associated with ecto-5'-nucleotidase (`NT5E` / CD73), which generates extracellular adenosine, a recognized driver of microenvironmental immune suppression and fibroblast activation.

---

### 2. Core Biological Programs

```
                     CORE BIOLOGICAL PROGRAMS IN CRC OS
                     
 ┌──────────────────────────────────┐      ┌──────────────────────────────────┐
 │ Program 1: TGF-β / EMT / ECM     │      │ Program 2: Intestinal Lineage    │
 │ Association: Risk (HR > 1)       │      │ Association: Protective (HR < 1) │
 │ Pathway: Hallmark EMT            │      │ Pathway: Intestinal Differentiation│
 └──────────────────────────────────┘      └──────────────────────────────────┘
 ┌──────────────────────────────────┐      ┌──────────────────────────────────┐
 │ Program 3: Mitochondrial OXPHOS  │      │ Program 4: Antigen Presentation  │
 │ Association: Protective (HR < 1) │      │ Association: Protective (HR < 1) │
 │ Pathway: Hallmark OXPHOS         │      │ Pathway: MHC Class I Presentation│
 └──────────────────────────────────┘      └──────────────────────────────────┘
```

#### Program 1: TGF-β Superfamily Signaling, EMT, and Extracellular Matrix Remodeling
* **Direction:** Risk-associated ($\text{HR} > 1$; adverse overall survival).
* **Major supporting genes:** `INHBB` ($\text{HR} = 1.433$), `ZEB1-AS1` ($\text{HR} = 1.372$), `MIR31HG` ($\text{HR} = 1.309$), `ITGBL1` ($\text{HR} = 1.299$), `TPM4` ($\text{HR} = 1.364$), `DCBLD2` ($\text{HR} = 1.408$), `ADAMTS18` ($\text{HR} = 1.263$).
* **Standardized Pathway:** Hallmark Epithelial Mesenchymal Transition (`MSigDB: M5930`) / KEGG TGF-beta Signaling Pathway (`hsa04350`).
* **Biological Rationale:** `INHBB` encodes the Inhibin Subunit Beta B (yielding Activin B), a TGF-$\beta$ family ligand known to activate Smad and non-Smad cascades. `ZEB1-AS1` and `MIR31HG` act as epigenetic and post-transcriptional enforcers of EMT and cellular senescence-associated secretory phenotypes (SASP). `ITGBL1` promotes myofibroblast/cancer-associated fibroblast (CAF) activation and TGF-$\beta$ stimulation, while `TPM4` and `ADAMTS18` mediate cytoskeletal reorganization and ECM proteolysis. Together, these genes define a mesenchymal transcriptomic state that facilitates local invasion and metastasis.
* **Evidence Strength & Limitations:** **High evidence strength.** Supported by multiple independent risk genes ($P < 10^{-4}$). **Limitation:** Bulk RNA sequencing cannot definitively resolve whether this signal originates from tumor cells undergoing EMT, infiltrating CAFs, or dense tumor stroma.

#### Program 2: Intestinal Epithelial Lineage Differentiation and Polarity Maintenance
* **Direction:** Protective-associated ($\text{HR} < 1$; favorable overall survival).
* **Major supporting genes:** `CDX2` ($\text{HR} = 0.748$), `CDX1` ($\text{HR} = 0.781$), `MYB` ($\text{HR} = 0.771$), `MYO5B` ($\text{HR} = 0.748$), `LGALS4` ($\text{HR} = 0.771$), `RAB11FIP4` ($\text{HR} = 0.736$).
* **Standardized Pathway:** GO Biological Process: Intestinal Epithelial Cell Differentiation (`GO:0002070`).
* **Biological Rationale:** `CDX2` and `CDX1` are master caudal-type homeobox transcription factors essential for specifying and maintaining colorectal mucosal identity. `MYO5B` (Myosin VB) and `RAB11FIP4` direct apical membrane trafficking and polarization in enterocytes. `LGALS4` (Galectin-4) is an intestine-specific cell-adhesion galectin expressed in mature luminal colonocytes. Their co-preservation indicates a differentiated luminal epithelial state, which is associated with lower histological grade and lower metastatic potential.
* **Evidence Strength & Limitations:** **High evidence strength.** `CDX2` is an established clinical biomarker in colorectal pathology. **Limitation:** Downregulation of these markers could indicate either true transcriptional dedifferentiation of tumor cells or a reduced proportion of non-neoplastic intestinal epithelium within low-purity tissue specimens.

#### Program 3: Mitochondrial Oxidative Phosphorylation (OXPHOS) and TCA Bioenergetics
* **Direction:** Protective-associated ($\text{HR} < 1$; favorable overall survival).
* **Major supporting genes:** `NDUFA9` ($\text{HR} = 0.689$), `ATP5B` ($\text{HR} = 0.748$), `ATP5G1` ($\text{HR} = 0.747$), `COA3` ($\text{HR} = 0.744$), `CS` ($\text{HR} = 0.754$), `OGDHL` ($\text{HR} = 0.686$), `ATP23` ($\text{HR} = 0.688$).
* **Standardized Pathway:** Hallmark Oxidative Phosphorylation (`MSigDB: M5936`) / KEGG Citrate Cycle (TCA Cycle) (`hsa00020`).
* **Biological Rationale:** `NDUFA9` (Complex I subunit), `COA3` (Complex IV assembly factor), and `ATP5B`/`ATP5G1` (Complex V subunits) form the core of the inner mitochondrial membrane respiratory chain. `CS` (Citrate Synthase) and `OGDHL` (Oxoglutarate Dehydrogenase Like) supply reducing equivalents ($\text{NADH}/\text{FADH}_2$) to drive electron transport. High expression of this mitochondrial program reflects intact aerobic respiration, which is characteristic of metabolic differentiation and contrasts with glycolytic, aggressive tumor phenotypes.
* **Evidence Strength & Limitations:** **Moderate-to-High evidence strength.** Consistently supported across multiple mitochondrial genes ($P < 10^{-4}$). **Limitation:** Transcript levels do not directly measure mitochondrial enzymatic activity, flux, or metabolic substrate preference.

#### Program 4: Antigen Presentation and Immune Surveillance
* **Direction:** Protective-associated ($\text{HR} < 1$; favorable overall survival).
* **Major supporting genes:** `TAPBPL` ($\text{HR} = 0.711$), `LGALS9` ($\text{HR} = 0.753$), `CCL15` ($\text{HR} = 0.753$), `CASP6` ($\text{HR} = 0.768$).
* **Standardized Pathway:** Reactome Antigen Processing-Cross Presentation (`R-HSA-1236975`) / KEGG Antigen Processing and Presentation (`hsa04612`).
* **Biological Rationale:** `TAPBPL` (TAP binding protein-like / TAPBP-R) functions as a dedicated chaperone facilitating peptide editing and MHC class I molecule assembly, enabling CD8+ T-cell recognition. `CCL15` recruits immune effector populations, while `LGALS9` acts in cell adhesion and immune signaling. Preserved antigen-presenting capability supports immune surveillance, suppressing metastatic seeding and disease progression.
* **Evidence Strength & Limitations:** **Moderate evidence strength.** **Limitation:** Bulk transcriptomics cannot confirm whether antigen presentation protein complexes are correctly assembled at the cell surface or functional in vivo.

---

### 3. Key Genes and Interaction Modules

```
                    KEY GENES AND INTERACTION MODULES
                    
   [ CDX2 ] ──(Regulatory/TF)──► [ MYO5B / LGALS4 ]  (Epithelial Identity)
      │
 (Antagonism)
      ▼
   [ ZEB1-AS1 ] ──(Regulatory)──► [ ZEB1 ] ──(Pathway Co-Membership)──► [ INHBB / ITGBL1 ] (EMT)
      │
      └─────────────────────────► [ TPM4 / ABL2 ] (Cytoskeleton)
```

#### 1. CDX2 (Caudal-Type Homeobox 2)
* **Statistical Association:** Protective ($\text{HR} = 0.748$, $P = 2.98 \times 10^{-5}$, $\text{FDR} = 0.0355$).
* **Role in Programs:** Master driver of Program 2 (Intestinal Differentiation).
* **Gene Interactions:**
  * Direct regulatory interaction with downstream intestinal genes (`MYO5B`, `LGALS4`), driving their transcription.
  * Functional antagonism (indirect relationship) with EMT transcription factors (e.g., ZEB family), suppressing mesenchymal expression.

#### 2. INHBB (Inhibin Subunit Beta B)
* **Statistical Association:** Strongest risk gene ($\text{HR} = 1.433$, $P = 2.00 \times 10^{-8}$, $\text{FDR} = 0.00109$).
* **Role in Programs:** Principal ligand driver for Program 1 (TGF-$\beta$ / EMT).
* **Gene Interactions:**
  * Pathway co-membership with `ITGBL1`, `ZEB1-AS1`, and downstream TGF-$\beta$/Smad signaling targets.
  * Indirect regulatory relationship with stromal remodeling factors like `TPM4` and `ADAMTS18`.

#### 3. ZEB1-AS1 (ZEB1 Antisense RNA 1)
* **Statistical Association:** Risk gene ($\text{HR} = 1.372$, $P = 9.83 \times 10^{-7}$, $\text{FDR} = 0.00865$).
* **Role in Programs:** Non-coding RNA regulator within Program 1 (EMT).
* **Gene Interactions:**
  * Direct locus regulation of its cognate gene `ZEB1` (epigenetic/transcriptional activation in *trans* or *cis*).
  * Co-expression network membership with mesenchymal structural genes (`TPM4`, `ITGBL1`).

#### 4. NDUFA9 (NADH:Ubiquinone Oxidoreductase Subunit A9)
* **Statistical Association:** Top protective gene ($\text{HR} = 0.689$, $P = 1.11 \times 10^{-6}$, $\text{FDR} = 0.00865$).
* **Role in Programs:** Anchor for Program 3 (Mitochondrial OXPHOS).
* **Gene Interactions:**
  * Direct physical protein-protein interaction (subunit of Mitochondrial Complex I) with other ETC proteins.
  * Pathway co-membership and co-expression with `ATP5B`, `ATP5G1`, `COA3`, and `CS`.

#### 5. NT5E (Ecto-5'-Nucleotidase / CD73)
* **Statistical Association:** Risk gene ($\text{HR} = 1.313$, $P = 4.33 \times 10^{-5}$, $\text{FDR} = 0.03939$).
* **Role in Programs:** Microenvironmental immunosuppression and stromal crosstalk (Program 1 / Immune regulation).
* **Gene Interactions:**
  * Pathway co-membership with purinergic signaling cascades (converting extracellular AMP to adenosine).
  * Indirect microenvironmental interaction with cytotoxic lymphocytes (suppressing immune activation) and CAFs.

#### 6. TAPBPL (TAP Binding Protein Like)
* **Statistical Association:** Protective gene ($\text{HR} = 0.711$, $P = 4.92 \times 10^{-6}$, $\text{FDR} = 0.01921$).
* **Role in Programs:** Anchor for Program 4 (Antigen Presentation).
* **Gene Interactions:**
  * Direct physical transient interaction with MHC Class I heavy chains and $\beta_2$-microglobulin within the endoplasmic reticulum.
  * Pathway co-membership with MHC Class I processing machinery.

#### 7. ITGBL1 (Integrin Subunit Alpha Beta Like 1)
* **Statistical Association:** Risk gene ($\text{HR} = 1.299$, $P = 1.96 \times 10^{-5}$, $\text{FDR} = 0.03061$).
* **Role in Programs:** Program 1 (TGF-$\beta$ / Stromal activation).
* **Gene Interactions:**
  * Co-expression with `INHBB` and `TPM4` in cancer-associated fibroblasts.
  * Functional involvement in TGF-$\beta$ release and matrix cross-linking.

#### 8. MYO5B (Myosin VB)
* **Statistical Association:** Protective gene ($\text{HR} = 0.748$, $P = 1.61 \times 10^{-5}$, $\text{FDR} = 0.02823$).
* **Role in Programs:** Program 2 (Epithelial Polarity and Trafficking).
* **Gene Interactions:**
  * Direct physical interaction with Rab small GTPases (e.g., `RAB11FIP4` pathway) during endosomal vesicle recycling.
  * Downstream regulatory target of the epithelial differentiation network anchored by `CDX2`.

#### 9. DCBLD2 (Discoidin, CUB and LCCL Domain Containing 2)
* **Statistical Association:** High-risk gene ($\text{HR} = 1.408$, $P = 9.86 \times 10^{-7}$, $\text{FDR} = 0.00865$).
* **Role in Programs:** Neuropilin-like receptor participating in RTK signaling, cell motility, and EMT (Program 1).
* **Gene Interactions:**
  * Direct physical and regulatory interactions with RTKs (e.g., EGFR, VEGFR) to facilitate receptor trafficking and endocytosis.
  * Co-expression with invasive structural markers (`ABL2`, `TPM4`).

#### 10. SLC2A3 (Solute Carrier Family 2 Member 3 / GLUT3)
* **Statistical Association:** Risk gene ($\text{HR} = 1.281$, $P = 1.47 \times 10^{-4}$, $\text{FDR} = 0.07217$).
* **Role in Programs:** Metabolic adaptation to hypoxia and microenvironmental energy demand.
* **Gene Interactions:**
  * Pathway co-membership with glycolytic networks under HIF-1$\alpha$ regulatory control.
  * Functional antagonism with mitochondrial OXPHOS genes (`NDUFA9`, `CS`).

---

### 4. Validation Priorities

```
                      PROPOSED VALIDATION PIPELINE
                      
  ┌────────────────────────┐      ┌────────────────────────┐
  │ 1. INHBB / TGF-β Axis  │      │ 2. Single-Cell / Deconv│
  │ (Therapeutic Target)   │      │ (Composition Check)    │
  └───────────┬────────────┘      └───────────┬────────────┘
              │                               │
              ▼                               ▼
  ┌────────────────────────┐      ┌────────────────────────┐
  │ 3. CDX2 / Lineage Axis │      │ 4. NT5E / CD73 Axis    │
  │ (Biomarker / Prognosis)│      │ (Interaction / Immune) │
  └───────────┬────────────┘      └───────────┬────────────┘
              │
              ▼
  ┌────────────────────────┐
  │ 5. OXPHOS vs. GLUT3    │
  │ (Mechanistic Bioener-  │
  │  getics Hypothesis)    │
  └────────────────────────┘
```

#### Priority 1: INHBB / Activin B Signaling Neutralization in High-Stroma CRC
* **Classification:** Therapeutic Target / Mechanistic Hypothesis.
* **Prioritization Rationale:** `INHBB` demonstrates the strongest adverse risk association ($\text{HR} = 1.433$, $P = 2.00 \times 10^{-8}$) in the dataset. As a secreted growth factor, it represents an actionable target for therapeutic monoclonal antibodies or soluble trap receptors.
* **Dataset Evidence:** Strong statistical significance ($P = 2.00 \times 10^{-8}$) coupled with co-enrichment of downstream stromal and EMT mediators (`ITGBL1`, `ZEB1-AS1`, `TPM4`).
* **External Evidence:** Activin B (homodimer of `INHBB`) promotes EMT and invasion in epithelial malignancies via Smad2/3 phosphorylation and crosstalk with the tumor microenvironment.
* **Next Steps:** Evaluate neutralizing antibodies against Activin B or ALK4/7 receptor inhibitors in patient-derived organoid (PDO) co-cultures with cancer-associated fibroblasts. Measure invasion assays and E-cadherin/Vimentin expression.
* **Confidence Level:** Supported Hypothesis.

#### Priority 2: Single-Cell Resolution Deconvolution of the Stromal/Epithelial Transcriptomic Axis
* **Classification:** Confounding or Composition Check.
* **Prioritization Rationale:** Distinguishing tumor cell-intrinsic transcriptional rewiring from microenvironmental cell-type composition changes (e.g., CAF infiltration, normal mucosal contamination) is critical for interpreting risk genes such as `TPM4`, `ITGBL1`, and `NT5E`.
* **Dataset Evidence:** Strong anti-correlation between mature enterocyte markers (`CDX2`, `MYO5B`, `LGALS4`) and stromal/EMT markers (`INHBB`, `TPM4`, `ADAMTS18`).
* **External Evidence:** Single-cell RNA sequencing (scRNA-seq) of CRC reveals that mesenchymal signatures in bulk transcriptomics are often driven by CAF abundance rather than complete epithelial-to-mesenchymal transdifferentiation of neoplastic cells.
* **Next Steps:** Apply digital deconvolution algorithms (e.g., CIBERSORTx, MuSiC) using CRC single-cell reference matrices on bulk transcriptomic datasets; validate via multiplexed immunohistochemistry (mIHC) or spatial transcriptomics on tissue microarrays (TMAs).
* **Confidence Level:** Established Evidence (that tissue composition confounds bulk RNA-seq); Exploratory Hypothesis (specific cell-type distribution for this gene set).

#### Priority 3: Clinical Biomarker Panel Combining CDX2 Preservation with NT5E (CD73) Stratification
* **Classification:** Biomarker.
* **Prioritization Rationale:** Combining markers from two independent functional domains (epithelial differentiation preservation via `CDX2` vs. microenvironmental adenosinergic immunosuppression via `NT5E`) could improve prognostic stratification beyond single-gene markers.
* **Dataset Evidence:** Both `CDX2` ($\text{HR} = 0.748$) and `NT5E` ($\text{HR} = 1.313$) demonstrate strong independent prognostic associations.
* **External Evidence:** Loss of CDX2 expression is a recognized marker of high-risk Stage II/III CRC. Elevated CD73 is linked to immune exclusion and poor response to immune checkpoint blockade.
* **Next Steps:** Retrospective IHC validation on independent, annotated clinical cohorts (e.g., stage-stratified CRC TMAs) using a combined protein risk score ($\text{CDX2}^{\text{low}}/\text{CD73}^{\text{high}}$ vs $\text{CDX2}^{\text{high}}/\text{CD73}^{\text{low}}$).
* **Confidence Level:** Supported Hypothesis.

#### Priority 4: Functional Impact of Adenosinergic Activity (NT5E) on Antigen Presentation (TAPBPL)
* **Classification:** Interaction / Network Hypothesis.
* **Prioritization Rationale:** The dataset shows opposing hazard associations for immunosuppressive adenosine generation (`NT5E`, $\text{HR} = 1.313$) and MHC class I antigen processing (`TAPBPL`, $\text{HR} = 0.711$).
* **Dataset Evidence:** Significant inverse hazard alignment ($\text{HR} > 1$ vs $\text{HR} < 1$) within immune and microenvironmental modules.
* **External Evidence:** Adenosine signaling via A2A/A2B receptors suppresses CD8+ T-cell activation and downregulates antigen presentation machinery in tumor cells.
* **Next Steps:** Co-culture assays combining CD73-inhibited tumor cells with autologous T-cells; quantify surface MHC-I expression, TAPBPL recruitment, and T-cell cytotoxicity under adenosine-rich vs adenosine-depleted conditions.
* **Confidence Level:** Exploratory Hypothesis.

#### Priority 5: Bioenergetic Shift (OXPHOS vs. GLUT3) as a Metabolic Dependency in Invasive CRC
* **Classification:** Mechanistic Hypothesis.
* **Prioritization Rationale:** Favorable survival is linked to mitochondrial OXPHOS genes (`NDUFA9`, `ATP5B`, `CS`), whereas high expression of the glucose transporter `SLC2A3` (GLUT3) correlates with poor survival.
* **Dataset Evidence:** `NDUFA9` ($\text{HR} = 0.689$) vs `SLC2A3` ($\text{HR} = 1.281$).
* **External Evidence:** Colorectal tumors undergoing EMT shift reliance from OXPHOS to enhanced glycolytic uptake via GLUT3 to survive hypoxic microenvironments.
* **Next Steps:** Perform Seahorse metabolic flux analysis (OCR vs. ECAR) on CRC cell lines with modulated CDX2/ZEB1 levels; test sensitivity to Complex I inhibitors (e.g., phenformin) versus GLUT3 inhibitors.
* **Confidence Level:** Supported Hypothesis.

---

### 5. Evidence Grounding

```
                     EVIDENCE GROUNDING MATRIX
                     
┌───────────────────────┬─────────────────────────────────────────────────┐
│ Evidence Category     │ Applied Dataset Features / Biological Nodes     │
├───────────────────────┼─────────────────────────────────────────────────┤
│ Direct Dataset        │ HRs, P-values, FDRs for INHBB, NDUFA9, CDX2     │
│ Pathway / Ontology    │ Hallmark EMT, Hallmark OXPHOS, GO Intestinal    │
│ PPI / Regulatory      │ NDUFA9 Complex I; CDX2-MYO5B regulation         │
│ Disease-Association   │ CDX2 loss in CRC clinical staging               │
│ Cell / Tissue-Specific│ CDX2, LGALS4 intestinal mucosal specificity      │
└───────────────────────┴─────────────────────────────────────────────────┘
```

* **Direct Evidence from Input Dataset:** 
  Includes hazard ratios, P-values, and FDR values indicating statistical associations with overall survival. Top statistically significant markers include `INHBB` ($\text{HR} = 1.433$, $\text{FDR} = 0.00109$), `SCARA3` ($\text{HR} = 1.377$, $\text{FDR} = 0.00243$), `NDUFA9` ($\text{HR} = 0.689$, $\text{FDR} = 0.00865$), and `ZEB1-AS1` ($\text{HR} = 1.372$, $\text{FDR} = 0.00865$).

* **Pathway and Ontology Evidence:** 
  Standardized MSigDB, KEGG, and GO annotations group these genes into coherent biological networks, including Hallmark EMT (`INHBB`, `ZEB1-AS1`, `TPM4`), Hallmark OXPHOS (`NDUFA9`, `ATP5B`, `COA3`), and GO Intestinal Epithelial Cell Differentiation (`CDX2`, `CDX1`, `MYO5B`, `LGALS4`).

* **Protein Interaction and Regulatory Evidence:** 
  Physical structural interactions within Mitochondrial Complex I (`NDUFA9`) and Complex V (`ATP5B`, `ATP5G1`) represent established physical complex associations. Regulatory interactions between `CDX2` and enterprise luminal epithelial promoters are supported by published ChIP-seq and transcriptional profiling studies.

* **Tissue- and Cell-Specific Expression Evidence:** 
  `CDX2`, `CDX1`, and `LGALS4` display strict tissue specificity for intestinal epithelium under physiological conditions. Their reduced expression in high-risk samples suggests either cellular dedifferentiation or a lower ratio of epithelial cells relative to tumor stroma.

* **Conflicting or Overlapping Evidence Considerations:** 
  * *Overlapping Sources:* Prognostic signals for `ITGBL1`, `TPM4`, and `ADAMTS18` likely reflect the same underlying biological variable: high stromal density (CAF infiltration / CMS4 subtype). They should be viewed as correlated features of a single biological program rather than independent prognostic mechanisms.
  * *Insufficient Evidence:* Available bulk transcriptomic data are insufficient to determine whether the prognostic association of `MIR31HG` or `ZEB1-AS1` depends on their specific non-coding RNA targets or broader chromosomal locus co-amplification.

---

### 6. Limitations and Alternative Explanations

#### 1. Tumor Purity and Stromal Cell Composition Confounding
* **Mechanism:** Bulk tumor RNA sequencing measures an average signal across cancer cells, cancer-associated fibroblasts (CAFs), endothelial cells, and immune infiltrates. High expression of risk genes (`TPM4`, `ITGBL1`, `INHBB`) may reflect high stromal content (low tumor purity) rather than aggressive transcriptomic phenotypes within the neoplastic cells themselves.
* **Resolution Strategy:** Perform single-cell RNA sequencing or spatial transcriptomics on tissue sections to evaluate cell type-specific expression profiles. Alternatively, apply computational deconvolution (e.g., ESTIMATE, CIBERSORTx) to adjust survival models for tumor purity.

#### 2. Confounding by Consensus Molecular Subtypes (CMS)
* **Mechanism:** Colorectal cancer encompasses four distinct Consensus Molecular Subtypes (CMS1–CMS4). The protective signal of `CDX2`/OXPHOS genes and the risk signal of `INHBB`/EMT genes closely match the intrinsic distinctions between CMS2/3 (epithelial/canonical) and CMS4 (mesenchymal/prometamorphic). The observed hazard ratios may primarily reflect this subtype distribution rather than independent gene-specific effects.
* **Resolution Strategy:** Perform subtype-stratified multivariable Cox proportional hazards modeling (e.g., evaluating `CDX2` or `INHBB` within CMS4 cases specifically).

#### 3. Unadjusted Clinical Covariates (Stage, Treatment, MSI Status)
* **Mechanism:** Tumor stage (Stage I–IV), Microsatellite Instability (MSI-H vs. MSS), and adjuvant fluoropyrimidine/oxaliplatin therapy strongly influence overall survival. If high `TAPBPL` or `LGALS9` expression correlates with MSI-H status (which carries a favorable early-stage prognosis), its protective effect may be mediated by MSI status rather than antigen presentation capacity alone.
* **Resolution Strategy:** Perform multivariable survival analyses incorporating clinical covariates (AJCC stage, MSI status, age, sex, and chemotherapy history).

#### 4. Broad and Non-Specific Mitochondrial Gene Enrichment
* **Mechanism:** Co-downregulation of multiple mitochondrial genes (`NDUFA9`, `ATP5B`, `CS`, `COA3`) in high-risk samples may reflect secondary cell stress, tissue necrosis, or altered organelle density in high-grade tumors, rather than a specific driver defect in oxidative phosphorylation.
* **Resolution Strategy:** Measure mitochondrial DNA (mtDNA) copy number, perform mitochondrial mass normalization (e.g., VDAC1 ratioing), and conduct functional metabolic flux profiling on viable fresh tissue specimens.

#### 5. Divergence Between mRNA Abundance and Protein/Enzymatic Function
* **Mechanism:** Transcript levels do not account for post-translational modifications, proteolytic cleavage, protein complex assembly dynamics, or subcellular localization. For example, `NT5E` (CD73) requires cell-surface localization and enzymatic cleavage of AMP to drive adenosine-mediated immunosuppression.
* **Resolution Strategy:** Validate transcriptomic findings using quantitative immunohistochemistry (IHC), Western blotting of membrane fractions, or enzymatic activity assays (e.g., malachite green assay for CD73 ecto-5'-nucleotidase activity) on matched frozen tissue samples.
